Kinnate Biopharma Inc (DELISTED) (KNTE:DL)
2.65
0.00 (0.00%)
USD |
NASDAQ |
Apr 03, 16:00
Kinnate Biopharma Cash from Operations (Quarterly): -17.36M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -17.36M |
| September 30, 2023 | -25.54M |
| June 30, 2023 | -29.42M |
| March 31, 2023 | -27.72M |
| December 31, 2022 | -23.75M |
| September 30, 2022 | -20.66M |
| June 30, 2022 | -23.54M |
| March 31, 2022 | -21.09M |
| Date | Value |
|---|---|
| December 31, 2021 | -22.52M |
| September 30, 2021 | -17.64M |
| June 30, 2021 | -17.46M |
| March 31, 2021 | -13.44M |
| December 31, 2020 | -13.78M |
| September 30, 2020 | -8.022M |
| June 30, 2020 | -5.709M |
| March 31, 2020 | -2.674M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-29.42M
Minimum
Jun 2023
-2.674M
Maximum
Mar 2020
-18.15M
Average
-19.15M
Median
Cash from Operations (Quarterly) Benchmarks
| XOMA Corp | -3.927M |
| Societal CDMO Inc (DELISTED) | 1.527M |
| NGM Biopharmaceuticals Inc (DELISTED) | -22.96M |
| Avrobio Inc | -8.031M |
| Landos Biopharma Inc | -4.969M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 22.70M |
| Free Cash Flow | -100.04M |
| Free Cash Flow Per Share (Quarterly) | -0.3685 |
| Free Cash Flow Yield | -81.06% |